Trials in activation phase

Current AGITG trials in activation phase are:

 

MONARCC:

Protocol Title: A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer

Study Chair: Dr Matthew Burge

Associate Oncology Program Manager: Cheryl Friend

Trial Coordinator: T.B.C.

Contact Email:  monarcc@ctc.usyd.edu.au

Detailed information will be available shortly on:  Australian and New Zealand Clinical Trials Registry

Trial Newsletter: None to date

Grants Awarded: 

  • AGITG Innovation Fund ($100,000)
  • Alan Bishop Fund ($20,000)

Design: A prospective randomised phase 2 study to assess the activity of panitumumab alone versus panitumumab plus 5FU as first line treatment for RAS wild type elderly patients with metastatic colorectal cancer

Key question: To evaluate the progression free survival and patient acceptability of both panitumumab alone and when given with 5FU as first line treatment in RAS wild type metastatic colorectal cancer.

 

 

 

 

Donate Now